Tahmid Rahman, MD
Cardiovascular Disease · Stonybrook, NYNPI 1982018537
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,469 of the $6,369 with a category attached, or 70.2%. 24 manufacturers reported payments, led by Novartis at 36.9% of the total. Reporting peaked in 2024 at $2,791 and has fallen 87.5% since, to $350 in 2025.
Across 79 payments — averaging $80.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$2K
- Amgen$2K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$340
- Boehringer Ingelheim$217
- Penumbra, Inc.$187
- Esperion Therapeutics, Inc.$168
- plus $1K from 18 others
Across 12 payments — averaging $17,626 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$124K
- Eli Lilly$88K
What the payments were for
- Consulting fees$1,90030%
- Food & beverage$4,46970%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 9 | $2,353 |
| Amgen | 25 | $2,071 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 9 | $340 |
| Boehringer Ingelheim | 5 | $217 |
| Penumbra, Inc. | 2 | $187 |
| Esperion Therapeutics, Inc. | 3 | $168 |
| Abbott | 1 | $145 |
| Abiomed | 1 | $127 |
| Philips North America LLC | 1 | $121 |
| Regeneron | 1 | $108 |
| Medtronic | 1 | $103 |
| Chiesi USA, Inc. | 4 | $97 |
| E.r. Squibb & Sons, L.L.C. | 6 | $82 |
| Vifor Pharma, Inc. | 1 | $40 |
| Regeneron Healthcare Solutions, Inc. | 1 | $36 |
| Bayer | 1 | $31 |
| United Therapeutics Corporation | 1 | $25 |
| Gilead | 1 | $21 |
| Pfizer | 1 | $20 |
| Cardinal Health 200 LLC | 1 | $19 |
| Lantheus Medical Imaging, Inc. | 1 | $18 |
| Johnson & Johnson | 1 | $15 |
| AstraZeneca | 1 | $12 |
| Astellas Pharma US Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Repatha$1,201
- LEQVIO$292
- Indigo System$171
- MitraClip System$145
- JARDIANCE$132
- Impella$127
- NEXLIZET$125
- NEXLETOL$125
- (5091) Amb Mon & Diag Und$121
- EVKEEZA$108
- Resolute$103
How this compares
$6,369 in reported general payments places this provider in the 75th percentile of 2,302 cardiovascular disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 152 | $220,211 |
| JardianceEmpagliflozin | 142 | $171,385 |
| Repatha SureclickEvolocumab | 118 | $103,222 |
| EntrestoSacubitril/Valsartan | 44 | $54,504 |
| XareltoRivaroxaban | 35 | $43,505 |
| Repatha SyringeEvolocumab | 50 | $29,121 |
| Praluent PenAlirocumab | 35 | $23,992 |
| FarxigaDapagliflozin Propanediol | 18 | $22,780 |
| BrilintaTicagrelor | 14 | $17,773 |
| VascepaIcosapent Ethyl | 26 | $15,357 |
| MounjaroTirzepatide | 11 | $11,266 |
| Metoprolol Succinate | 443 | $6,746 |
| Ezetimibe | 244 | $6,362 |
| Rosuvastatin Calcium | 246 | $5,038 |
| Atorvastatin Calcium | 503 | $4,572 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $20 | $220,211152 claims |
| Boehringer IngelheimJardiance | $217 | $171,385142 claims |
| NovartisEntresto | $2,353 | $54,50444 claims |
| Johnson & JohnsonXarelto | $15 | $43,50535 claims |
| AstraZenecaFarxiga, Brilinta | $12 | $40,55332 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,302 cardiovascular disease providers in New York.
Other cardiovascular disease in Stonybrook
- Roger HajjarNew York$5.2M
- Szilard VorosStony Brook$3.7M
- Gregg StoneNew York$2M
- Augustin DelagoAlbany$1.8M
- Philippe GenereuxNew York$1.3M
- Adam RosenbluthNew York$1.1M
- Luigi di BiaseBronx$978K
- Vijay IyerAmherst$855K
- Megha PrasadNew York$813K
- Ronald DagostinoLake Success$782K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.